The article highlights three biotech and semiconductor stocks that have more than doubled in the past 12 months but may have further upside potential. Abivax is advancing obefazimod for ulcerative colitis with strong clinical results. Krystal Biotech is generating strong revenue growth from its approved DEB treatment Vyjuvek with significant market expansion opportunities. Marvell Technology is capitalizing on AI infrastructure spending demand for custom chips as an alternative to Nvidia's GPUs.

Abivax SA resumed trading of its ordinary shares on Euronext Paris on July 1, 2026, following a temporary halt. The company announced the pricing of an oversubscribed and upsized public offering of American Depositary Shares, increased from the previously announced $600M to $800M at $125.00 per share.

Abivax SA announced a temporary suspension of its ordinary shares trading on Euronext Paris starting July 1, 2026 at market opening. The suspension is related to the company's public offering of American Depositary Shares (ADS) in the United States to confirm investor allocations and announce final offering terms. Trading is expected to resume around 15:30 CEST the same day.

Abivax SA announced a temporary trading halt of its ordinary shares on Euronext Paris effective July 1, 2026, from market opening at 9:00 a.m. CEST. The halt is in connection with the company's public offering of American Depositary Shares in the United States to allow for allocation confirmation and pricing announcement. Trading is expected to resume at approximately 3:30 p.m. CEST the same day.

Abivax stock rose 3.46% on Thursday despite concerns following the release of Phase 3 trial data for obefazimod in ulcerative colitis. While the drug met primary endpoints with remission rates exceeding 50%, reported cancer cases during the trial have raised safety concerns among investors. The stock trades below its moving averages, with momentum indicators suggesting weakness.

Abivax, a French biotech company, saw its stock surge 1,000% over the past year following strong phase 3 results for obefazimod, a non-immunosuppressant ulcerative colitis treatment. However, recent maintenance trial data revealed safety concerns including cancer cases, causing a sharp stock decline. The author argues the market may be overreacting, noting that cancer cases were mostly in older patients and may be unrelated to the drug, while obefazimod still shows strong efficacy and oral convenience advantages.

Abivax and Viking Therapeutics are two biotech companies that could potentially double in value by 2030 if their leading drug candidates succeed in clinical trials and regulatory approval. Abivax is developing obefazimod for ulcerative colitis, while Viking Therapeutics is advancing VK2735 for weight loss treatment. Both stocks carry significant risk due to their clinical-stage status and lack of approved products.

The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.

Abivax CEO Marc de Garidel downplayed acquisition rumors and indicated the company plans to pursue equity and debt financing after releasing key Phase 3 trial data for obefazimod in late Q2 2026. With $614.42 million in cash providing runway into Q4 2027, the French biotech aims to strengthen its financial position ahead of potential FDA approval and commercialization, while seeking commercial partners for markets outside the U.S.

Abivax and Nektar Therapeutics are clinical-stage biotech companies with promising drug candidates that could make them attractive acquisition targets. Abivax is developing obefazimod for inflammatory diseases with phase 3 trial data expected in Q2, while Nektar's rezpegaldesleukin shows strong potential for eczema treatment. Both companies have sufficient funding and could be acquired by major pharmaceutical companies at premium valuations.

Cormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage therapies for neurological disorders with strong cash reserves of $926 million.

ACT Capital Management invested $7.25 million in Viking Therapeutics, acquiring 206,100 shares. Viking, a clinical-stage biotech company, is developing obesity and metabolic disorder treatments, with its lead candidate VK2735 showing promising Phase 2 results of up to 14.7% weight reduction. The company has $706 million in cash runway and is advancing multiple clinical programs including Phase 3 trials.